Insider filing · PASG

Lynx1 Capital Management LP bought $264K of Passage Bio (PASG)

Executed Nov 25 2024, disclosed Nov 27 2024, 2 days later.

Over the 21 trading sessions from the disclosed entry session (Nov 27 2024), the stock returned -16.6% (delay-adjusted); from the execution session (Nov 25 2024), +28.9%. Derived: entry at the session's open, exit at the close 20 sessions later.

LL Lynx1 Capital Management LP 10% owner profile →

Lynx1 Capital Management LP (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in Passage Bio, Inc. (PASG). Across 1 priced purchase filing, the average 21-session return was +1.5% from execution and -0.7% from disclosure (delay-adjusted; derived). The largest single filing was $854K of KRRO (77,299 sh across 3 lots, as filed), executed Oct 22.

PASG Passage Bio, Inc. PASG · Healthcare · 6 filings in 24 months ticker →

Healthcare · Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→